Aeon Biopharma Inc (AEON)

$1.26 +0.06 (5.00%)
Market Cap 14.21M
Revenue (ttm) 0.00
Net Income (ttm) 42.01M
EPS (ttm) N/A
PE Ratio 0.45
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 413,800
Avg Vol 208,010
Day's Range N/A - N/A
Shares Out 11.84M
Stochastic %K 65%
Beta 0.72
Analysts Strong Sell
Price Target $6.10

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 354 6499
Address:
5 Park Plaza, Suite 1750, Irvine, United States
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 24 at 4:54 AM
$AEON broke the 70percent RSI
0 · Reply
_Crocodileteeth
_Crocodileteeth Feb. 24 at 12:26 AM
Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $AEON $LSH $SLS $FOSL looking good
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 10:21 PM
$AEON Not too bad of a day. Lets hope for a good week everyone.
1 · Reply
Stackdoe101
Stackdoe101 Feb. 23 at 8:10 PM
$AEON
1 · Reply
Gonzalo1006
Gonzalo1006 Feb. 23 at 8:06 PM
$AEON
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 8:03 PM
$AEON Looks like some resistance possibly at 1.40ish?
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 23 at 7:22 PM
$AEON reassurance
0 · Reply
Maggielein
Maggielein Feb. 23 at 7:21 PM
$AEON AEON held an important “Biosimilar Product Development (BPD) Type 2a” meeting with the FDA in January 2026. This is a formal dialogue regarding regulatory requirements, but it is not an approval decision. • The company expects to receive the official meeting minutes from the FDA within approximately 30 days, which will be critical in determining the next development steps (e.g., additional studies). We will see
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 7:05 PM
$AEON The volume! Looking good!
0 · Reply
VinWeezel
VinWeezel Feb. 23 at 6:53 PM
$AEON
0 · Reply
Latest News on AEON
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Jan 21, 2026, 4:05 PM EST - 4 weeks ago

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Dec 19, 2025, 6:00 PM EST - 2 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Dec 15, 2025, 4:05 PM EST - 2 months ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

Nov 20, 2025, 8:30 AM EST - 3 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 14, 2025, 8:30 AM EST - 3 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Nov 13, 2025, 8:30 AM EST - 3 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Oct 1, 2025, 8:00 AM EDT - 5 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 19, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 25, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Apr 21, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

AEON Biopharma Announces CEO Transition

Mar 27, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Announces CEO Transition

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Provides Update on Development Pipeline

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 24 at 4:54 AM
$AEON broke the 70percent RSI
0 · Reply
_Crocodileteeth
_Crocodileteeth Feb. 24 at 12:26 AM
Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $AEON $LSH $SLS $FOSL looking good
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 10:21 PM
$AEON Not too bad of a day. Lets hope for a good week everyone.
1 · Reply
Stackdoe101
Stackdoe101 Feb. 23 at 8:10 PM
$AEON
1 · Reply
Gonzalo1006
Gonzalo1006 Feb. 23 at 8:06 PM
$AEON
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 8:03 PM
$AEON Looks like some resistance possibly at 1.40ish?
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 23 at 7:22 PM
$AEON reassurance
0 · Reply
Maggielein
Maggielein Feb. 23 at 7:21 PM
$AEON AEON held an important “Biosimilar Product Development (BPD) Type 2a” meeting with the FDA in January 2026. This is a formal dialogue regarding regulatory requirements, but it is not an approval decision. • The company expects to receive the official meeting minutes from the FDA within approximately 30 days, which will be critical in determining the next development steps (e.g., additional studies). We will see
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 7:05 PM
$AEON The volume! Looking good!
0 · Reply
VinWeezel
VinWeezel Feb. 23 at 6:53 PM
$AEON
0 · Reply
BryceyBoy
BryceyBoy Feb. 23 at 2:38 PM
$AEON Decent rise before the market opened today. Hoping that's a sign that it will continue today.
1 · Reply
TheLaughingStock1
TheLaughingStock1 Feb. 23 at 1:07 PM
$AEON When are we getting the results/meeting minutes from the FDA meeting from January? I thought it would be by Feb 21st, as that's 30 days ?
1 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 22 at 4:17 AM
$AEON the low float may help break the RSI
1 · Reply
VXRT007
VXRT007 Feb. 21 at 11:50 PM
$AEON https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications
1 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 21 at 12:47 AM
$AEON timing of those 3m was the exact date of the fda deadline
0 · Reply
VinWeezel
VinWeezel Feb. 20 at 12:57 PM
$AEON ceo was granted 3 million shares. Congrats Robert.
2 · Reply
FoxySprout
FoxySprout Feb. 20 at 12:32 PM
$AEON On close watch…
0 · Reply
BryceyBoy
BryceyBoy Feb. 19 at 9:56 PM
$AEON Good closing to the day. Lets hope we close tomorrow high as well and next week might be some real good news!
1 · Reply
RaiderNation5413
RaiderNation5413 Feb. 19 at 6:40 PM
$AEON All signs point to major growth. I've held through the last reverse split, and accumulated since. Patience is a must in my case, but not a problem when you believe in a company and it's product. To the moon!....eventually.
1 · Reply
HalEugene
HalEugene Feb. 19 at 5:28 PM
$AEON @Traidn Why are you worried about where other people put their Benjamin's?
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Feb. 19 at 5:25 PM
$AEON $1.09 is back
0 · Reply
SebNo1234
SebNo1234 Feb. 19 at 5:13 PM
$AEON $EOLS $OPEN $MREO
0 · Reply